Latest & greatest articles for Prostate Cancer Staging

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Prostate Cancer Staging or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Prostate Cancer Staging and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Prostate Cancer Staging

1. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. (Abstract)

Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data.To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer.The Men's (...) Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) was a randomized clinical trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Society of Urological Pathology grade group = 1 in those <70 years and ≤2 in those ≥70 years), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL. Enrollment occurred from January 2011 to August 2015; 24-month follow-up

2020 JAMA

3. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis Full Text available with Trip Pro

Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis Bone lesions on prostate MRI often raise concern about metastases. This study aimed to evaluate the prevalence of bone metastases on staging prostate MRI and evaluate associations between their MRI features and clinical/pathologic characteristics.Retrospective, IRB-approved study of 3765 patients undergoing prostate MRI for newly diagnosed PCa between 2000 and 2014 (...) . The reference standard to calculate the prevalence of bone metastases was bone biopsy and/or ≥1-year follow-up after MRI. In a subsample of 228 patients, the MRI characteristics of bone lesions were recorded by two radiologists independently. Associations between MRI and clinical/pathologic findings, including National Comprehensive Cancer Network (NCCN) risk categories, were calculated.57/3765 patients (1.5%, 95% CI 1.2-2.0%) had bone metastases. No patient with NCCN low-risk PCa (Gleason < 7, PSA < 10 ng

2017 Abdominal radiology (New York)

4. Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy Full Text available with Trip Pro

Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy There is growing evidence supporting incorporating multiparametric (mp) magnetic resonance imaging (MRI) scans into risk stratification, active surveillance, and treatment paradigms for prostate cancer. The purpose of our study was to determine whether demographic disparities exist in staging MRI utilization for prostate cancer patients.An (...) across all risk groups and black or nonprivate insurance patients in the low risk group were less likely to undergo staging prostate MRI scans. Further research should investigate these differences to ensure equitable utilization across all demographic groups considering the burden of prostate cancer disparities.

2016 Advances in radiation oncology

5. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer Full Text available with Trip Pro

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer Prostate cancer is a prevalent public health problem worldwide. While imaging has played a major role in this disease, there still remain many challenges and opportunities. Positron emission tomography with various physiologically based radiotracers is fundamentally suited to interrogate this biologically and clinically heterogeneous disease along the course of its (...) natural history. In this article, I review briefly the published evidence for the use of positron emission tomography with 18F-fluorodeoxyglucose, 11C-acetate, and 18F- or 11C-choline in the imaging evaluation of prostate cancer. Although the focus of the article will be on these radiotracers given the accumulated experience with them, but I will also comment on the outlook for the use of other emerging PET radiotracers such as those targeted to the prostate-specific membrane antigen and the amino

2016 Abdominal radiology (New York)

6. Diagnosis, Staging and Treatment of Patients with Prostate Cancer

in Ireland, 2010-2012 87 Figure 7 Five year net survival: Prostate Cancer in Ireland 88 Figure 8 Economic Literature Review Results 1377 | A National Clinical Guideline | Diagnosis, staging and treatment of patients with prostate cancer Cancer is a major healthcare challenge. Each year in Ireland, approximately 19,000 people are diagnosed with malignant cancer. Cancer is the second leading cause of death in Ireland after diseases of the circulatory system. Deaths from cancer averaged about 8,800 deaths (...) at three levels. (C) 2.4.2.1 For determining tumour extent in prostate core biopsies, when there are multiple foci of prostate cancer in a single core separated by benign intervening stroma, it is suggested that the collapsing method is used (i.e. where intervening benign tissue is excluded from the measurement). (D) 2.4.3.1 For each biopsy site the presence of biopsies positive for carcinoma and the ISUP 2005 Gleason score should be reported. The pathologists should assign a separate Gleason score

2016 National Clinical Guidelines (Ireland)

7. Prostate Cancer?Pretreatment Detection, Surveillance, and Staging

, not of it” [1], the reality is that prostate cancer is second only to lung cancer as a cause of death from malignancy in American men. Specifically, in 2015, an estimated 220,800 American men were diagnosed with prostate cancer and 27,540 died of the disease [2]. In addition to the personal toll of these deaths, the direct economic cost of prostate cancer in the Unites States has been estimated at approximately $10 billion per year [3]. As with other malignancies, the primary goal during baseline evaluation (...) of prostate cancer is disease characterization; that is, establishing disease extent, both local and distant, and aggressiveness. Determination of tumor aggressiveness is ultimately the most important factor, since this drives patient outcome. Several special circumstances make the accurate baseline evaluation of prostate cancer particularly challenging: ? The currently available standard clinical tools used to evaluate prostate cancer, such as digital rectal examination, serum prostate-specific antigen

2016 American College of Radiology

8. National Clinical Guideline for the Diagnosis, Staging and Treatment of Prostate Cancer

, staging and treatment of patients with prostate cancer Cancer is a major healthcare challenge. Each year in Ireland, approximately 19,000 people are diagnosed with malignant cancer. Cancer is the second leading cause of death in Ireland after diseases of the circulatory system. Deaths from cancer averaged about 8,800 deaths per year during 2010-2012, representing about 30% of all deaths in that period (NCRI, 2014a). Cancer incidence data from the National Cancer Registry Ireland (NCRI) and population (...) ) addressed this question. However, there is a lack of consensus elucidating which patient groups should have an MRI for staging. MRI is now the most commonly used imaging technique for T-staging men with prostate cancer. (NICE, 2014) The accuracy of staging of the disease may be improved by MRI which can reduce unnecessary treatment-related morbidity when there is no possibility of cure (Sanchez-Chapado et al., 1997, Bates et al., 1997). Multiparametric MRI may add additional information and can help

2015 Health Service Executive (Ireland) - Clinical Guidelines

9. Weighted Versus Unweighted Charlson Score to Predict Long-term Other-cause Mortality in Men with Early-stage Prostate Cancer (Abstract)

Weighted Versus Unweighted Charlson Score to Predict Long-term Other-cause Mortality in Men with Early-stage Prostate Cancer Clinicians need a simple yet accurate method to predict other-cause mortality to inform medical decision making for men with prostate cancer (PCa).To compare weighted and unweighted Charlson Comorbidity Index scores in predicting long-term, other-cause mortality in men with early-stage PCa.A retrospective cohort study of 1482 men with early-stage PCa diagnosed in 1998 (...) from other causes in men with early-stage prostate cancer.Published by Elsevier B.V.

2014 EvidenceUpdates

10. Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer (Abstract)

Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa.To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice.This was a multicenter retrospective cohort (...) on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa.Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2014 EvidenceUpdates

11. [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer]

[Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer] Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer] Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging (...) of prostate cancer] Atienza Merino G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Atienza Merino G. Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata. [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer] Santiago de Compostela: Galician Agency

2013 Health Technology Assessment (HTA) Database.

12. Xofigo (radium Ra 223 dichloride) - To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs

Xofigo (radium Ra 223 dichloride) - To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Xofigo (radium Ra 223 dichloride) Injection Company: Bayer HealthCare Pharmaceuticals Application No.: 203971 Approval Date: 5/15/2013 Persons with disabilities having problems

2013 FDA - Drug Approval Package

13. Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer

. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama. 2005;294(4):433-439. 76. Cox JD, Stoffel TJ. The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate. Cancer. 1977;40(1):156-160. 77. Scardino PT. The prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol. 1983;1(4):243-252. 78. Freiha FS, Bagshaw MA. Carcinoma of the prostate: results of post-irradiation biopsy (...) patients with erectile dysfunction after irradiation for prostate cancer. Supporting Documents ? ACR Appropriateness Criteria ® Overview ? Evidence Table References 1. Hanks GE, Hanlon AL, Schultheiss TE, et al. Conformal external beam treatment of prostate cancer. Urology. 1997;50(1):87-92. 2. Perez CA, Cosmatos D, Garcia DM, Eisbruch A, Poulter CA. Irradiation in relapsing carcinoma of the prostate. Cancer. 1993;71(3 Suppl):1110-1122. 3. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1

2013 American College of Radiology

14. PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer

the general circulation. Elevated serum PSA level has become an important marker of many prostate diseases – including benign prostatic hyperplasia, prostatitis, and prostate cancer, the focus of this document. Prostatic intraepithelial neoplasia (PIN) does not appear to raise serum PSA levels. 1,2 The Use of PSA Testing for Pretreatment Staging of Prostate Cancer Routine radiographic staging, such as with bone scan, computed tomography (CT), or magnetic resonance imaging (MRI), or surgical staging (...) PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis

2013 American Urological Association

15. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study Full Text available with Trip Pro

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.Whole blood was collected into PAXgene tubes from patients with castration-resistant (...) prostate cancer and patients with prostate cancer selected for active surveillance. In stage I (derivation set), patients with castration-resistant prostate cancer were used as cases and patients under active surveillance were used as controls. These patients were recruited from The Royal Marsden Hospital NHS Foundation Trust (Sutton, UK) and The Beatson West of Scotland Cancer Centre (Glasgow, UK). In stage II (validation-set), patients with castration-resistant prostate cancer recruited from

2012 EvidenceUpdates

16. Magnetic resonance spectroscopy for the initial diagnosis and staging of prostate, brain, breast and other cancers: horizon scanning report

Magnetic resonance spectroscopy for the initial diagnosis and staging of prostate, brain, breast and other cancers: horizon scanning report Magnetic resonance spectroscopy for the initial diagnosis and staging of prostate, brain, breast and other cancers: horizon scanning report Magnetic resonance spectroscopy for the initial diagnosis and staging of prostate, brain, breast and other cancers: horizon scanning report Smartt P Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smartt P. Magnetic resonance spectroscopy for the initial diagnosis and staging of prostate, brain, breast and other cancers: horizon scanning report. Christchurch: Health Services Assessment Collaboration (HSAC). HSAC Report 2(8). 2009 Authors' conclusions • It appears that MRS has now advanced beyond the ‘experimental’ stage and that there has been some diffusion

2009 Health Technology Assessment (HTA) Database.

17. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

18. Patient education materials about the treatment of early-stage prostate cancer: a critical review. (Abstract)

Patient education materials about the treatment of early-stage prostate cancer: a critical review. To ensure that patients make informed medical decisions, patient education materials must communicate treatment risks and benefits.To survey publicly available patient education materials and assess their suitability to support informed decision making in early-stage prostate cancer.Cross-sectional review of Internet, print, and multimedia sources.University data analysis laboratory.The content (...) , and plain-language reviews were evaluated by 1 reviewer. The criteria reflect the authors' focus on informed decision making. Other aspects of health education may require a different evaluation template.Currently available patient education materials on early-stage prostate cancer treatment do not contain comprehensive information about the risks and benefits of each treatment. To assist patients and physicians in choosing among prostate cancer treatment options, a new generation of materials is needed.

2004 Annals of Internal Medicine

19. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis

Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 DARE.

20. Prostate cancer staging: should MR imaging be used? A decision analytic approach

Prostate cancer staging: should MR imaging be used? A decision analytic approach Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 NHS Economic Evaluation Database.